Safety Profile of Retatrutide: Comprehensive Overview from Clinical Data

Introduction

A drug’s safety profile builds up step by step as it moves through clinical development. What we know about retatrutide’s safety comes from Phase 1, Phase 2 and Phase 3 clinical trials. Phase 1 and Phase 2 trials together gave the drug to several hundred participants for up to 48 weeks. The Phase 3 TRIUMPH-4 trial (December 2025) greatly expanded this safety database with a larger, more diverse population treated for up to 68 weeks. Since then the other pivotal trials have reported: TRANSCEND-T2D-1 (40 weeks), TRIUMPH-1, TRIUMPH-2 and TRIUMPH-3 (80 weeks each), and the head-to-head TRANSCEND-T2D-2 trial (80 weeks, topline October 28, 2026). This page centres on the TRIUMPH-4 and Phase 2 data; the TRIUMPH-1, TRIUMPH-2 and TRIUMPH-3 pages give their safety tables. Limitations remain: treatment periods are shorter than you would expect in clinical practice for chronic conditions like obesity and type 2 diabetes.

Below we pull together the published safety data from the retatrutide program, including the Phase 3 TRIUMPH-4 results, compare them with the known safety profile of the wider incretin drug class, and set out the safety questions that are still open.

Gastrointestinal Adverse Events

Overview

Gastrointestinal (GI) side effects were the most common adverse events in every retatrutide trial, as you would expect from GLP-1 receptor agonism. They follow predictably from GLP-1R activation in the gut and brainstem, which slows stomach emptying, changes bowel movement and triggers nausea through the area postrema.

Nausea

Nausea was the single most commonly reported adverse event in the Phase 2 obesity trial. It was reported in 11% of the placebo group and 14% to 60% of the retatrutide groups over 48 weeks: 45% at 12 mg, and 60% in the 8 mg group that started at 4 mg rather than 2 mg (NEJM 2023, Table 3). Key characteristics of nausea events:

• Timing: Most nausea occurred during the dose-escalation phase (first 8-12 weeks) and diminished as participants adapted to stable maintenance doses
• Severity: The majority of nausea events were classified as mild to moderate; severe nausea was uncommon
• Duration: Most episodes were transient, lasting days rather than weeks
• Discontinuation: Nausea alone was an infrequent cause of treatment discontinuation

Diarrhea

Diarrhea was most prominent during the escalation phase. In the Phase 2 obesity trial it was reported in 11% on placebo and 9% to 20% of retatrutide groups (15% at 12 mg). Severe diarrhea was uncommon, and most events resolved without intervention.

Vomiting

Vomiting occurred in 3% to 26% of retatrutide groups in the Phase 2 obesity trial (19% at 12 mg), against 1% on placebo. Vomiting tended to co-occur with nausea episodes and was similarly concentrated in the early treatment period. The rate of vomiting was broadly comparable to that observed with other GLP-1R agonists at their efficacious doses.

Constipation

Constipation was reported in 6% to 16% of retatrutide groups in the Phase 2 obesity trial, against 3% on placebo. This effect may relate to the gastric motility changes associated with GLP-1R agonism. This may seem odd alongside diarrhea, but different participants had different GI effects, and constipation and diarrhea rarely occurred in the same person.

Decreased Appetite

Decreased appetite is really an intended drug effect rather than a pure adverse event, but a large share of participants reported it. It shows that GLP-1R and GIPR are suppressing appetite in the brain, and it tracks the amount of weight lost.

GI Tolerability in Context

Retatrutide’s overall GI side effect profile is in line with the incretin drug class. Compared to semaglutide 2.4 mg (the highest approved obesity dose), retatrutide’s GI event rates are broadly similar, though direct comparisons are limited by differences in trial design, escalation schedules, and patient populations. Adding GIPR and GCGR agonism does not seem to make GI tolerability much worse than the GLP-1R component alone would.

Phase 3 TRIUMPH-4 Gastrointestinal Data

The Phase 3 TRIUMPH-4 trial (December 2025) provided updated GI adverse event rates from a larger, more diverse study population treated for up to 68 weeks. At the 12 mg dose, nausea was reported in 43.2% of participants, diarrhea in 33.1%, vomiting in 20.9% and constipation in 25.0% (placebo 10.7%, 13.4%, 0% and 8.7%). In the Phase 2 obesity trial the 12 mg group had nausea in 45%, diarrhea in 15%, vomiting in 19% and constipation in 16%. So nausea and vomiting were similar, while diarrhea and constipation were more common in TRIUMPH-4. The Wegovy (semaglutide 2.4 mg) label lists nausea in 44%, diarrhea in 30% and vomiting in 24%.

Phase 3 trials enroll larger and more varied populations and run longer, which can capture more adverse events. The GI profile remains consistent with the incretin-based therapy class and was managed through dose escalation.

Dysesthesia: A New Phase 3 Safety Signal

TRIUMPH-4 identified dysesthesia (abnormal sensations such as tingling, numbness or burning) as a new safety signal that had not stood out in Phase 2. It became clearly more common as the dose rose:

Dysesthesia was generally mild in severity and infrequently led to treatment discontinuation. The signal is thought to be linked to glucagon receptor activity, which distinguishes retatrutide from GLP-1-only agonists and dual GIP/GLP-1 agonists such as tirzepatide. Neither semaglutide nor tirzepatide have shown comparable dysesthesia rates in their clinical programs, supporting a GCGR-specific mechanism.

How much this finding matters clinically still needs to be worked out. Key questions include whether dysesthesia resolves with continued treatment, whether it is associated with specific neurological findings on examination, and whether it affects treatment adherence in real-world settings. The later Phase 3 trials reported lower rates at 12 mg: 12.5% in TRIUMPH-1, 7.3% in TRIUMPH-2 and 6.4% in TRIUMPH-3. Pooled analyses and, later, post-marketing surveillance will be needed to fully understand this signal.

Treatment Discontinuation

Discontinuation due to adverse events is a key measure of tolerability. In the Phase 2 obesity trial:

GI events were the most common reason for stopping. The rate was highest at 12 mg, but the pattern across the smaller arms (33 to 35 people each) is uneven: a 2 mg start lowered discontinuation in the 4 mg arms but not in the 8 mg arms. A lower starting dose did consistently reduce nausea.

For the Phase 2 type 2 diabetes trial, the published abstract reports GI adverse events in 35% of retatrutide participants (13% at 0.5 mg to 50% in the 8 mg fast-escalation group), 13% on placebo and 35% on dulaglutide. It does not give a rate of stopping because of side effects.

Phase 3 TRIUMPH-4 Discontinuation Data

Phase 3 TRIUMPH-4 reported updated discontinuation rates:

The 18.2% rate at 12 mg is modestly higher than the 16% observed in Phase 2 and exceeds the rates in the US labels for semaglutide 2.4 mg (6.8%) and tirzepatide (4.8% to 6.7% across doses). In TRIUMPH-1 it was 11.3% at 12 mg (placebo 4.9%). Discontinuation was driven primarily by gastrointestinal intolerance, though dysesthesia may have contributed in some cases.

Cardiovascular Safety

Heart Rate

Consistent with other GLP-1R agonists, retatrutide was associated with an increase in heart rate. In the Phase 2 obesity trial, heart rate rose with dose, peaked at 24 weeks and declined at 36 and 48 weeks. The authors noted that glucagon and GLP-1 can both speed the heart and described the increases as similar to those reported for GLP-1 receptor agonists. The main text of the paper does not give the size of the rise. Cardiac arrhythmia events (mostly supraventricular arrhythmias and conduction disorders, mild to moderate) were reported in 11% of the 12 mg group and 3% on placebo. For comparison, the Wegovy label reports mean increases of 1 to 4 beats per minute over placebo.

How much a small rise in heart rate matters alongside large weight loss and metabolic improvement is still debated, but regulators watch it closely. Cardiovascular outcome trials (CVOTs) of GLP-1R agonists (semaglutide, liraglutide) have demonstrated net cardiovascular benefit despite the heart rate increase, but retatrutide-specific cardiovascular outcome data are not yet available.

Blood Pressure

Retatrutide was associated with reductions in both systolic and diastolic blood pressure in Phase 2 trials. Mean reductions in systolic blood pressure ranged from approximately 4-8 mmHg, depending on dose and baseline values. These improvements fit with the weight loss and metabolic gains seen and are a favorable cardiovascular safety signal.

Lipid Profile

Phase 2 data showed improvements in lipid parameters, including reductions in triglycerides and low-density lipoprotein (LDL) cholesterol, and increases in high-density lipoprotein (HDL) cholesterol. These changes are directionally favorable for cardiovascular risk but require confirmation in larger and longer studies.

Cardiovascular Outcome Data

No dedicated cardiovascular outcomes trial (CVOT) has been completed for retatrutide; TRIUMPH-Outcomes (~10,000 participants) is running. TRIUMPH-3, in 1,949 adults with established cardiovascular disease, reported an exploratory in-study MACE-5 hazard ratio of 0.82 (95% CI 0.55-1.22), which is not statistically significant. While the existing data show favorable trends in cardiovascular risk factors, definitive evidence of cardiovascular safety or benefit will require either a dedicated CVOT or post-marketing surveillance. Regulatory agencies may require a CVOT as a condition of approval or as a post-marketing commitment.

Hepatic Effects

Liver Enzymes

In the Phase 2 trials, retatrutide was associated with generally stable or improved liver enzyme levels (ALT, AST). Given the marked reduction in liver fat content observed in treated participants, improvements in liver enzymes are consistent with reduced hepatic steatosis and inflammation. No significant hepatotoxicity signals were identified.

Liver Fat

The dramatic drop in liver fat (up to approximately 82% relative reduction at the highest dose) is one of retatrutide’s most notable secondary findings. While this is primarily an efficacy observation, it has safety implications: reducing hepatic steatosis may lower the risk of progression to steatohepatitis, fibrosis, and cirrhosis. However, the long-term hepatic safety of sustained glucagon receptor agonism, including effects on hepatic protein synthesis, bile acid metabolism, and liver regeneration, requires continued monitoring.

Pancreatic Safety

Concerns about pancreatitis and pancreatic neoplasia have been raised for the incretin-based therapy class as a whole, although large meta-analyses and long-term outcome studies have not confirmed a causal association. In the Phase 2 retatrutide trials, no cases of confirmed pancreatitis were reported. Pancreatic enzyme elevations (amylase, lipase) were monitored, and while asymptomatic elevations were observed in some participants, these did not progress to clinical pancreatitis.

Metabolic Safety Parameters

Glycemic Safety

In the obesity trial (participants without diabetes), no significant hypoglycemia was reported. The glucose-dependent insulinotropic mechanism of GLP-1R and GIPR agonism inherently minimizes hypoglycemia risk, as insulin secretion is stimulated only when blood glucose is elevated. The glucagon receptor component, which promotes hepatic glucose output, provides an additional safeguard against hypoglycemia.

In the type 2 diabetes trial, the rate of hypoglycemia was low and was generally associated with concomitant sulfonylurea or insulin use rather than retatrutide alone. This is consistent with the known pharmacology and with the experience of other incretin-based agents.

Thyroid Safety

GLP-1R agonists carry a class-wide precautionary label regarding medullary thyroid carcinoma (MTC), based on preclinical findings of C-cell tumors in rodents exposed to GLP-1R agonists. The clinical relevance of this rodent finding to humans is uncertain, as the density of GLP-1 receptors on human thyroid C-cells is much lower than in rodents. In Phase 2 retatrutide trials, calcitonin levels (a biomarker for C-cell activity) were monitored and did not show clinically meaningful elevations. However, the sample sizes and treatment durations are insufficient to draw definitive conclusions about thyroid neoplasia risk.

Gallbladder Events

Rapid weight loss from any cause, including pharmacotherapy, is associated with an increased risk of gallbladder events (cholelithiasis, cholecystitis). In the Phase 2 obesity trial, a small number of gallbladder-related adverse events were reported in the active treatment groups, consistent with the known association between significant weight loss and gallstone formation. This risk is expected to be managed clinically through standard monitoring and is not unique to retatrutide.

Injection Site Reactions

Injection site reactions, including redness, swelling, itching, and pain at the injection site, were reported at low rates and were generally mild and transient. No significant allergic or anaphylactic reactions to retatrutide were reported in the Phase 2 program.

Immunogenicity

The formation of anti-drug antibodies (ADAs) was assessed in Phase 2 trials. Some participants developed treatment-emergent ADAs, but not many. Having ADAs did not seem to go with reduced efficacy or more adverse events, so on current data immunogenicity does not look like a significant clinical concern. Longer-term immunogenicity data from Phase 3 trials will give a firmer answer.

What Is Not Yet Known

Several key safety questions are still open. The Phase 3 TRIUMPH program and any post-marketing surveillance will address them:

Long-Term Safety

The longest treatment durations reported for retatrutide are 80 weeks, in TRIUMPH-1 (published in the New England Journal of Medicine on September 29, 2026), TRIUMPH-2, TRIUMPH-3 and TRANSCEND-T2D-2, with a 104-week extension in a TRIUMPH-1 subgroup. For a drug intended for chronic use in obesity and diabetes, safety data over multiple years are essential. Long-term effects on bone density (given the potential for GIP-mediated bone effects during weight loss), muscle mass preservation, nutritional status, and organ function require extended follow-up.

Uncommon Adverse Events

Phase 2 trials are too small to reliably detect adverse events that occur in fewer than approximately 1-2% of people. The Phase 3 program, with thousands of participants, has far more statistical power to pick up less common safety signals.

Special Populations

Limited data are available for retatrutide in populations such as:

• Older adults (age >65 years)
• Patients with significant renal impairment
• Patients with established cardiovascular disease (beyond the 80-week TRIUMPH-3 trial)
• Patients with a history of pancreatitis
• Patients with severe hepatic impairment
• Pediatric and adolescent populations

Reproductive Safety

Teratogenicity data in humans are not available for retatrutide. Based on the known effects of weight loss and metabolic changes on reproductive function, as well as the pharmacology of GLP-1R agonists, reproductive safety studies will be important for informing prescribing decisions in women of childbearing potential.

Drug Interactions

While the proteolytic metabolism of retatrutide suggests a low risk of CYP-mediated drug-drug interactions, the effect of slowed gastric emptying on the absorption of co-administered oral medications has not been extensively characterized. This pharmacokinetic interaction, which has been documented for other GLP-1R agonists, could affect the bioavailability of oral medications with narrow therapeutic windows.

Weight Regain After Discontinuation

The trajectory of weight and metabolic parameters after discontinuation of retatrutide has not been studied in controlled trials. Based on the experience with other incretin-based weight loss therapies, weight regain after discontinuation is expected, but the magnitude and time course with triple agonism specifically are unknown.

Summary and Perspective

Based on Phase 2 and Phase 3 TRIUMPH-4 data, retatrutide’s safety profile is broadly what you would expect from an incretin-based drug. Gastrointestinal side effects are still the main tolerability concern. They rise with dose and can be managed with gradual dose escalation. TRIUMPH-4 GI rates at 12 mg (nausea 43.2%, diarrhea 33.1%, vomiting 20.9%) are comparable to semaglutide 2.4 mg; nausea and vomiting were similar to the Phase 2 12 mg group, while diarrhea was higher. Several safety measures, including blood pressure, lipids and liver enzymes, continue to trend in a good direction.

Dysesthesia, the new safety signal found in TRIUMPH-4 (20.9% at 12 mg vs. 0.7% placebo), is an important finding that needs continued monitoring. It is usually mild, but this glucagon receptor-linked effect sets retatrutide’s safety profile apart from single- and dual-agonist incretin drugs.

The wider Phase 3 TRIUMPH program, with more trials in people with diabetes and MASLD, will add to the safety picture. Long-term data beyond 80 weeks, post-marketing surveillance and real-world evidence will feed into the regulatory benefit-risk review that decides whether this triple agonist reaches clinical practice.